Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: Skye Bioscience Completes Drug Production for Phase 1 Clinical Study
https://ceo.ca/@GlobeNewswire/skye-bioscience-completes-drug-production-for-phase
NEWS: Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
https://ceo.ca/@GlobeNewswire/skye-bioscience-files-definitive-proxy-statement-and
NEWS OUT: Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience
https://ceo.ca/@newsfile/emerald-health-therapeutics-receives-court-approval
These guys are full of it. Shareholders speak and they dont listen. Just another example of the scam. Cant stand this company(s) BS.
All anyone has to do is look at the chart and the current criminal proceeding to realize EMHTF is crooked.
News: Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience
https://ceo.ca/@newsfile/emerald-health-therapeutics-inc-provides-update-on
Cant say I blame the shareholders. EMHTF is trash (ran by a Dhillon) and their is the brother Punit Dhillon running this one so not sure shareholder guidance will be heeded
BRIEF-Shareholders Oppose Plan Of Arrangement Between Emerald Health Therapeutics And Skye Biosciences Inc
6:06am ET, 08/04/2022 - Reuters
Aug 4 (Reuters) - Emerald Health Therapeutics Inc:
* GROUP OF SHAREHOLDERS OPPOSE PLAN OF ARRANGEMENT BETWEEN EMERALD HEALTH THERAPEUTICS AND SKYE BIOSCIENCES INC.
* OPPOSING SHAREHOLDERS OF EMERALD HEALTH THERAPEUTICS SAY THEY OPPOSE ANNOUNCED PLAN OF ARRANGEMENT BETWEEN EMERALD AND SKYE BIOSCIENCES INC Source text for Eikon: Further company coverage:
Skye Bioscience Updates Phase 1 Timeline.
https://www.stocktitan.net/news/SKYE/skye-bioscience-updates-phase-1-rq325hooer12.html
Wow! Talk about at the buzzer. They hit their Q2 approval goal.
Let's see if we can execute on the timeline for starting the trial + interim data this year, then final data in Q1 next year!
(From their corporate presentation):
SBI-100 OE: PHASE 1
? Q1-22: Completion of GLP toxicology studies
? Q2-22: AUS Human Research Ethics Committee (HREC) approval to start Phase 1 study
? Q3-22: Phase 1 interim data
? Q1-23: Phase 1 final data
Long-awaited HREC approval FINALLY lands. Phase 1 human trials set to start!
https://www.newsfilecorp.com/release/129574/Skye-Bioscience-Receives-Australian-Ethics-Committee-Approval-to-Start-FirstinHuman-Phase-1-Study-of-SBI100-Ophthalmic-Emulsion?src=stocktwits
Our CEO Punit Dhillon will be presenting at an investor Zoom call today for shareholders and investors at 4:30pm ET . They are also presenting to institutional investors at the HC Wainwright conference next week. Exciting times for this company. I'm hoping for developments in the near term. Looking forward to getting an update on the call today!! Register hear to attend:
https://www.eventbrite.com/e/skye-bioscience-inc-webinar-5192022-registration-341385472137?utm_source=eventbrite&utm_medium=email&utm_content=follow_notification&utm_campaign=following_published_event&utm_term=Skye+Bioscience%2C+Inc.-Webinar+5%2F19%2F2022&aff=ebemoffollowpublishemail
Emerald already owes 25% of Skye,
https://whalewisdom.com/stock/lglrd
NEWS OUT...
Skye Bioscience hires CMAX to run its phase 1 study of lead candidate SBI-100 OE for glaucoma
https://ca.proactiveinvestors.com/companies/news/980839?SNAPI
Skye just filed a 10-K with 83 sections and 10 exhibits. Check it out!
https://last10k.com/sec-filings/skye/0001516551-22-000004.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=skye
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
https://ceo.ca/@nasdaq/skye-bioscience-reports-positive-results-for-sbi-100
Who else is adding right now? I've been able to average down to $.06
That's what most of the long holders think. Covid delayed a lot with the Australian trials.
this guy said they were going in the clinic and they completed a preIND w FDA. that's significant step fwd if anything materializes. that was a milestone for past 3years on their presentations if they actually moved past this step with the cash they claim to have on hand this this thing could move to phase 2 fairly quickly...could it be???
so quiet here
Skye Bioscience (SKYE) -
Please register to attend SKYE's Zoom presentation next week with Punit Dhillon, CEO. There will be a quick review of the PPT with live Q&A at the conclusion. The network is intended for Accredited Investors and shareholders.
Please register using this link:
https://www.amazon.com/dp/B01N9FXMW5?tag=drawnacom-20&linkCode=osi&th=1&psc=1&dn_platform=website
We should start moving in december...finaly
Is it just me or is chart looking a lot like last 2 breakouts above .20
no i did not.. i sold at 0.07
this hit almost 0.04 today
Good luck here
You sold and took a loss on the low.. Bold move
sold and took a loss here.
I was an investor with Nemus and become one when Skye was created
but now 500 million outstanding?
before it was under 200million
Dilution is a killer.
good luck
Skye recently updated its clinical development strategy and timeline for its Phase I study, focused on safety and tolerability in 48 healthy volunteers, which is being initiated in Q2-22 in Australia.
I'll believe it when I see it. I've seen this data when they were NMUS, then when they were EMBI, now SKYE has managed to regurgitate the same useless press release. This isn't some new company this is same bag of crap it was 3 names ago. Another Dhillon dumpster fire...outstanding
Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
https://www.globenewswire.com/news-release/2021/10/21/2318363/0/en/Skye-Bioscience-Sponsored-Research-Presented-at-American-Association-of-Pharmaceutical-Scientists-Meeting-PharmSci-360.html
Yep when Company starts issuing shares to fund operations I'm out i sold... Seen this dog and pony show too many times...
they just created another 80M shares w warrants that need to be sold
Punit way to driver shareholder value. This will be the story of an incompetent idiot who churns and burns this shell to zero. Way to go asshole
This what happens when you have press release mentioning Emerald. LOL!!!
Published
39 mins ago
on September 24, 2021
A bill to federally legalize marijuana will be voted on by the House Judiciary Committee next week, the panel announced on Friday... https://www.marijuanamoment.net/house-committee-will-vote-on-federal-marijuana-legalization-bill-next-week-days-after-banking-reform-advances/
CNBC FAST MONEY pot stock are big winners today... Due to the House Passing of the safe banking act... https://www.cnbc.com/video/2021/09/23/pot-stocks-are-big-winners-today-due-to-enthusiasm-over-new-bill.html
Awesome News Here.. The U.S. House of Representatives on Tuesday approved an amendment to protect banks that service state-legal marijuana businesses from being penalized by federal regulators. It passed on a voice vote, and no member requested a roll call. The measure is now attached to large-scale defense spending legislation. https://www.marijuanamoment.net/u-s-house-approves-marijuana-banking-reform-as-part-of-defense-spending-bill/
$SKYE Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360
read://https_www.otcdynamics.com/?url=https%3A%2F%2Fwww.otcdynamics.com%2Fskye-skye-bioscience-announces-thcvhs-late-breaking-preclinical-abstracts-selected-by-american-association-of-pharmaceutical-scientists-meeting-pharmsci-360%2F
News 9-14-2021 Change in Director of Principal officer... https://m.marketscreener.com/quote/stock/SKYE-BIOSCIENCE-INC-111314073/news/SKYE-BIOSCIENCE-INC-Change-in-Directors-or-Principal-Officers-Other-Events-Financial-Statement-36429741/
Time to Buy Pot Stocks!
After waves and waves of marijuana legalization, this industry has held true. The Senate is poised to legalize it at the federal level presenting an incredible opportunity for investors. Global sales were $24.6 billion in 2020, and they're expected to skyrocket to $97.35 billion by 2026.. https://finance.yahoo.com/news/profit-marijuana-without-touching-plant-110011890.html
Positive News for SKYE: https://finance.yahoo.com/news/skye-bioscience-completes-thcvhs-ind-123000510.html
SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, has successfully completed genotoxicity studies of THCVHS required prior to beginning its planned Phase 1 clinical study in Australia. Skye is initially developing THCVHS as a treatment of glaucoma.
Genotoxicity safety studies are required by both the Australian Therapeutic Goods Administration and the U.S. Food & Drug Administration prior to initiating human trials and were completed at BioReliance Corporation under Good Laboratory Practices regulations, which meet the standards for both agencies. BioReliance is the world’s leading provider of safety testing services and includes among its customers many of the largest pharmaceutical, biopharmaceutical, and chemical companies around the globe.
“Genotoxicity data are a prerequisite to enter into human trials in all major markets. Although the safety profile for the active pharmaceutical ingredient, THC, is well-recognized, this was the first time these studies were performed with our proprietary molecule THCVHS, a prodrug of THC,” said Punit Dhillon, CEO of Skye Bioscience. “We are pleased to have successfully completed these studies and continue to advance our nonclinical requirements prior to initiating our first-in-human trial, as well as future clinical trials in the US.”
Two studies were carried out to assess the genotoxicity potential of THCVHS. The first was a mammalian cell micronucleus assay, which is designed to determine a compound’s ability to generate chromosomal aberrations and considered to be one of the most reliable assays in determining genotoxicity. The second study was a reverse bacterial mutagenesis assay, also referred to as the Ames test, which assesses the ability of a compound to generate gene mutations. Both assays produced negative results indicating that THCVHS is not a genotoxic compound, clearing a key step to allow for human trials.
About THCVHS
THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development to treat glaucoma. Through the application of rational drug design, Skye has chemically modified THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. THCVHS enables enhanced local delivery of the drug into the eye, provides significant lowering of intraocular pressure, minimal systemic exposure, and potential for neuroprotection.
About Skye Bioscience
Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead program, THCVHS, is focused on treating glaucoma, a disease with no cure and the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.
Followers
|
137
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6316
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |